Interstitial Lung Disease News

The historical climate events of the past summer may have been eye-opening for all, but the health of patients with respiratory diseases and conditions has been particularly threatened due to these exposures.

SAN DIEGO — TNF inhibitors demonstrate comparable risks for hospitalization and death vs. non-TNF agents in patients with rheumatoid arthritis-associated interstitial lung disease, according to data presented at ACR Convergence 2023.

The prevalence of patients with interstitial lung disease who receive treatment varied across countries, with some sex- and race-based differences, according to results published in CHEST.

Knowing that interstitial lung abnormalities heighten interstitial lung disease and all-cause mortality risk, it is important that pulmonologists know how to recognize and distinguish these abnormalities.

SAN DIEGO — Shortness of breath, male sex, age and elevated inflammatory markers are all more predictive of new interstitial lung disease in systemic sclerosis than disease duration, according to data presented at ACR Convergence 2023.

SAN DIEGO — Monitoring of rheumatoid arthritis-associated interstitial lung disease remains highly variable and “suboptimal” in the real world, according to a speaker at ACR Convergence 2023.

Patients with interstitial lung disease and surfactant-related gene mutations showed progressive lung function decline and reduced survival that was comparable to that of other ILD groups, according to results published in CHEST.

Patients with asthma, COPD and interstitial lung disease have reduced SARS-CoV-2 vaccine-specific antibody, B-cell and T-cell responses, which signals poorer protection against COVID-19, according to results published in ERJ Open Research.

The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that lowered the rate of percent-predicted FVC decline among patients with progressive pulmonary fibrosis.

HONOLULU — Treatment with nintedanib plus pirfenidone resulted in a similar frequency of adverse events as monotherapy among patients with idiopathic pulmonary fibrosis, according to a systemic review presented at the CHEST Annual Meeting.